U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386730) titled 'A Study of Psychedelics in Healthy Older Adults With Low Well-being' on Jan. 20.
Brief Summary: This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being.
The main questions it aims to answer are, does psilocybin:
1. Acutely increase complexity of EEG activity in older adults with low well-being, as modulated by the presence of biomarkers of Alzheimer's disease (AD) pathology.
2. Longitudinally decrease plasma markers of neuroinflammation, as modulated by the presence of biomarkers of AD pathology.
3. ...